1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Leqembi Set For Japan Launch After Twisty Pricing Process

Close Monitoring Under Conditional Approval

 
• By Lisa Takagi

Eisai/Biogen's Alzheimer's drug will be launched in Japan on 20 December with a lower price premium than Eisai was negotiating for after back-and-forth reimbursement negotiations, and strict use and monitoring restrictions.

Eisai has faced tough pricing negotiation with the MHLW for lecanemab, although both sides recognize its value.
Eisai faced tough Japan price negotiations for Leqembi, but both sides recognized value • Source: Shutterstock

Japan’s Ministry of Health, Labour and Welfare (MHLW) has set the initial reimbursement price for Eisai Co., Ltd./Biogen, Inc.’s Alzheimer's drug Leqembi (lecanemab) under the national health insurance (NHI) scheme, paving the way for a market launch in the country on 20 December. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

AstraZeneca Logs Japan Growth Despite Price Cuts

 
• By Lisa Takagi

AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By Ian Haydock

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

More from Focus On Asia

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.